Press Releases

See the latest from ProtoKinetix

Review our press releases for information about our current research, recent findings and key milestones. If you want to follow along our journey of cell survival, subscribe to our newsletter so you never miss an update.
Therapeutic application:
Sort By:
Marietta, Ohio, July 7, 2020                                                                                                                ProtoKinetix, Incorporated ( (the “Company” or “ProtoKinetix”) (OTCQB:PKTX), a clinical-stage biomedical company, provides the following update regarding upcoming news in its Dry Eye Disease Program.   Dry Eye Disease (DED) – ProtoKinetix is expecting closure of agreements for the first steps in a roll-out of a new product […]
Marietta, Ohio, March 24, 2020 ProtoKinetix, Incorporated ( (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced an update to the Press Release of January 24, 2020. We have now completed the sterilization, quality assurance, labeling of the AAGP® (PKX-001) and are ready to ship the final product to the University of […]
Marietta, Ohio, March 19, 2020 ProtoKinetix, Incorporated ( (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) recently filed for patent protection for new applications of its AAGP® molecule.  During recent testing conducted by EyeCRO of Oklahoma City, using a well-established animal model for dry eye disease (DED), it was observed that AAGP® may have a substantial effect on […]
Marietta, Ohio, Feb. 19, 2020 ProtoKinetix, Incorporated ( (the “Company” or “ProtoKinetix”) (OTCQB: PKTX) announces the progress of screening PKX-001 for cardiometabolic disorders. “Using isolated cardiac cells, we demonstrated that PKX-001 exerts cardioprotective effects in cells that are exposed to stress induced by nutrient overload or cardiotoxic drugs. Specifically, PKX-001 minimized cardiac cell damage and […]
Marietta, Ohio, February 11, 2020                                                                                                      ProtoKinetix, Incorporated ( (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) recently filed for patent protection for a new application of its AAGP® molecule.  During recent testing at The University of British Columbia, where photo receptors were transplanted into animal models, it was observed that AAGP® may have had a role […]
Jan 24, 2020
Marietta, Ohio ProtoKinetix, Incorporated ( (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces that the Company has taken procession of an additional 200 grams of GMP grade PKX-001 (AAGP®) molecule. We are shipping sufficient molecule to Iotron Industries in British Columbia for sterilization.  The sterilization process is a 1-week turnaround. After sterilization there will be one more […]

Subscribe for updates

Get alerts about company news and key findings directly in your inbox.

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.

Picture of a molecule
Picture of a molecule

Leave a Reply

Your email address will not be published. Required fields are marked *